A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...

Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial ...

Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.

New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.

Less than a month after taking over as interim CEO of Legend Biotech, Alan Bash is signaling continuity rather than a reset. Bash joined Legend in October 2024 to lead its Carvykti business after two ...